| Health / Medical Topics |
Raf Kinase Inhibitor LGX818
An orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. (NCI Thesaurus)
YOU MAY ALSO LIKE
Any substance that inhibits Raf Kinase, an enzyme active in signal transduction in the Ras pathway. Inhibition of Raf kinase may result…
A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood and <10% blasts in the…
A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood. Approximately 25% of cases…
Refractory anemia with excess blasts associated with significant reticulin fibrosis of the bone marrow.
An orally available, hydrochloride salt form of radotinib, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor…
A radioactive gas that is released by uranium, a substance found in soil and rock. Breathing in too much radon can damage…
